Share your contact details to receive free updated sample copy/pages of the recently published edition of Neuropsychiatric Drugs Market Report 2023.
Key Insights from Neuropsychiatric Drugs Market Report
"Global Neuropsychiatric Drugs market size 2022 was XX Million. Neuropsychiatric Drugs Industry compound annual growth rate (CAGR) will be XX% from 2023 till 2030."
Neuropsychiatric Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Neuropsychiatric Drugs Market Report Description
Market Dynamics such as Drivers, Restraints, Opportunities, Trends data
Neuropsychiatric Drugs Industry Dynamics
- Market Drivers of Neuropsychiatric Drugs: The key factors which influence the overall sales demand for Neuropsychiatric Drugs Industry in a positive way. Market drivers help you understand the impact on market growth. With this information you can predict how said market is likely to grow in the coming year.
- Market Restraints of Neuropsychiatric Drugs: Restraints are the negative factors which hinder the market growth and development in the near future. Some of the restraining factors including strict government regulations, supply chain disruptions, changing consumer preference are affecting the market growth in the near future. For example, the outburst of COVID-19 affected the most of the industries. Restraining factors are important to analyse on account of companies can develop strategies to overcome their negative impact on the growth of the market.
- Market Opportunities of Neuropsychiatric Drugs: Market opportunities are expected to open up growth window for the new entrants in the market. It helps to understand unmet needs or an untapped potential in the market.
- Market Trends of Neuropsychiatric Drugs: (This information will be part of the paid report version.)
Base Year | 2022 |
Historical Data Time Period | 2018-2022 |
Forecast Period | 2023-2030 |
Report Edition | 7th Edition (2023) |
Last Update | Last Updated In April 2023 |
Next Report Edition | June 2023 (Pre-Booking Available) |
Market Forecast/Projection Time Period | 2023-2030 |
Report Format | PDF | PPT | Excel | Word | Bi |
Report ID | CMR656983 |
Neuropsychiatric Drugs Market Report 2023 (Global Edition) Table of Content differs according to the user License selection. Current Displayed TOC is for the Single User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report. Specific section/s of report can be ordered at a discounted price. If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Table of Content (Revenue USD Edition), (Enquire about Volume/Consumption Edition Data)
- 1.1 Global Neuropsychiatric Drugs Industry Introduction
- 1.2 Objectives of the Study
- 1.3 USP of the Report
- 1.4 Who is this report for?
- 1.5 Designing of Market Scope
- 1.5.1 Neuropsychiatric Drugs Market Segmentation
- 1.5.1 Neuropsychiatric Drugs Market Regional Fragmentation
- 1.5.1 Neuropsychiatric Drugs Market Players
- 1.6 Report Duration
- 1.7 List of Stakeholders
- 2.1 Neuropsychiatric Drugs Market Report 2023 Research Methodology
- 2.2 Systematic Research Approach
- 2.2.1 Primary Research
- 2.2.1.1 Key Data from Primary
- 2.2.1.2 Primary Interviews with Experts
- 2.2.1.3 Key Industry Insights
- 2.2.1.4 Questionnaire
At Cognitive Market Research, we have designed questionnaire focused on Neuropsychiatric Drugs Market for the statistical study. This questionnaire is the key part of our research methodology which is shared with number of Neuropsychiatric Drugs industry experts of entire value chain, located across the globe. This study help us to gather accurate quantitative and qualitative data for the final report.
- 2.2.1.5 Breakdown of Primaries
- 2.2.2 Secondary Research
- 2.2.2.1 Key Data from Secondary
- 2.2.2.2 Paid Sources
- 2.2.2.3 Public Sources
- 2.2.1 Primary Research
- 2.3 Market Size Estimation
- 2.3.1 Top-Down Approach
- 2.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 2.3.1 Bottom-UP Approach
- 2.3.1.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 2.3.1 Top-Down Approach
- 2.4 Market Breakdown and Data Triangulation
- 2.5 Research Assumptions
- 3.1 Global Neuropsychiatric Drugs Market Size 2018 – 2030, (USD Million)
- 3.2 Global Neuropsychiatric Drugs Value, Absolute & Opportunity Analysis
- 3.3 Global Neuropsychiatric Drugs Market Y-o-Y Growth Rate Projection by Region (2023 - 2030)
- 3.4 Global Neuropsychiatric Drugs Market Statistics 2022: Snapshot
- 4.1 Neuropsychiatric Drugs Introduction
- 4.2 Global Neuropsychiatric Drugs Market Statistics by Regions (2018-2030)
- 4.2.1 North America Neuropsychiatric Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.2 Europe Neuropsychiatric Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.3 Asia Pacific Neuropsychiatric Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.4 Latin America Neuropsychiatric Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.5 Middle East and Africa Neuropsychiatric Drugs Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.3 Global Neuropsychiatric Drugs Market Size (2018-2030)
- 4.3.1 Global Neuropsychiatric Drugs Revenue Status and Outlook (2018-2030)
- 4.4 Global Neuropsychiatric Drugs Market Price Analysis by Regions (2018-2030)
- 5.1 Global Neuropsychiatric Drugs Market Revenue and Share by Manufacturers (2018-2022)
- 5.2 Global Neuropsychiatric Drugs Industry Mergers and Acquisition Analysis
- 5.3 Global Neuropsychiatric Drugs New Launches Analysis
- 5.4 Company Categorization
- 5.5 Global Neuropsychiatric Drugs Top Winning Strategies, by Manufacturers (2018-2022)
- 7.1 Neuropsychiatric Drugs Industrial Dynamics
- 7.1.1 Global Neuropsychiatric Drugs Market Drivers
- 7.1.2 Global Neuropsychiatric Drugs Market Restrains
- 7.1.3 Global Neuropsychiatric Drugs Market Opportunities
- 7.1.4 Global Neuropsychiatric Drugs Market Trends
- 7.2 Neuropsychiatric Drugs Market Attractiveness Analysis
- 7.1.1 Market Attractiveness Analysis by Type Segment
- 7.1.2 Market Attractiveness Analysis by Application Segment
- 7.3 PESTEL Analysis for Neuropsychiatric Drugs Market
- 7.3.1 Political Factors
- 7.3.2 Economic Factors
- 7.3.3 Social Factors
- 7.3.4 Technological Factors
- 7.3.5 Legal Factors
- 7.3.6 Environmental Factors
- 7.4 Porter’s Five Forces Analysis for Neuropsychiatric Drugs Market
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of Substitutes
- 7.4.4 Threat of New Entrants
- 7.4.5 Degree of Competition
- 7.5 COVID-19 Impact on Neuropsychiatric Drugs Industry
- 7.4.1 Overall Impact of COVID-19 on Neuropsychiatric Drugs Industry
- 7.4.2 Post COVID-19 Impact and Recovery Analysis
- 7.4.3 Influencing Factors
- 7.6 Consumer Preference Analysis for Neuropsychiatric Drugs Market
- 7.7 Patent Analysis of Neuropsychiatric Drugs
- 7.8 Neuropsychiatric Drugs Industrial Chain Analysis
- 7.9 Manufacturing Cost Analysis
- 8.1 Novartis
- 8.1.1 Novartis Company Basic Information, and Sales Area
- 8.1.2 Novartis Business Segment/ Overview
- 8.1.3 Novartis Financials
- 8.1.3.1 Investment in Research and Development
- 8.1.3.2 Novartis Sales Revenue (2018-2022)
- 8.1.3.3 Novartis Market Share (2018-2022)
- 8.1.4 Novartis Recent Developments
- 8.1.5 Novartis Business Strategy
- 8.1.6 Novartis Management Change
- 8.1.7 Novartis SWOT Analysis
- 8.1.7.1 Strength
- 8.1.7.2 Weakness
- 8.1.7.3 Opportunity
- 8.1.7.4 Threats
- 8.1.8 Novartis COVID-19 Impact Analysis
- 8.2 Pfizer
- 8.2.1 Pfizer Company Basic Information, and Sales Area
- 8.2.2 Pfizer Business Segment/ Overview
- 8.2.3 Pfizer Financials
- 8.2.3.1 Investment in Research and Development
- 8.2.3.2 Pfizer Sales Revenue (2018-2022)
- 8.2.3.3 Pfizer Market Share (2018-2022)
- 8.2.4 Pfizer Recent Developments
- 8.2.5 Pfizer Business Strategy
- 8.2.6 Pfizer Management Change
- 8.2.7 Pfizer SWOT Analysis
- 8.2.7.1 Strength
- 8.2.7.2 Weakness
- 8.2.7.3 Opportunity
- 8.2.7.4 Threats
- 8.2.8 Pfizer COVID-19 Impact Analysis
- 8.3 Otsuka
- 8.3.1 Otsuka Company Basic Information, and Sales Area
- 8.3.2 Otsuka Business Segment/ Overview
- 8.3.3 Otsuka Financials
- 8.3.3.1 Investment in Research and Development
- 8.3.3.2 Otsuka Sales Revenue (2018-2022)
- 8.3.3.3 Otsuka Market Share (2018-2022)
- 8.3.4 Otsuka Recent Developments
- 8.3.5 Otsuka Business Strategy
- 8.3.6 Otsuka Management Change
- 8.3.7 Otsuka SWOT Analysis
- 8.3.7.1 Strength
- 8.3.7.2 Weakness
- 8.3.7.3 Opportunity
- 8.3.7.4 Threats
- 8.3.8 Otsuka COVID-19 Impact Analysis
- 8.4 Allergan
- 8.4.1 Allergan Company Basic Information, and Sales Area
- 8.4.2 Allergan Business Segment/ Overview
- 8.4.3 Allergan Financials
- 8.4.3.1 Investment in Research and Development
- 8.4.3.2 Allergan Sales Revenue (2018-2022)
- 8.4.3.3 Allergan Market Share (2018-2022)
- 8.4.4 Allergan Recent Developments
- 8.4.5 Allergan Business Strategy
- 8.4.6 Allergan Management Change
- 8.4.7 Allergan SWOT Analysis
- 8.4.7.1 Strength
- 8.4.7.2 Weakness
- 8.4.7.3 Opportunity
- 8.4.7.4 Threats
- 8.4.8 Allergan COVID-19 Impact Analysis
- 8.5 Eli Lilly
- 8.5.1 Eli Lilly Company Basic Information, and Sales Area
- 8.5.2 Eli Lilly Business Segment/ Overview
- 8.5.3 Eli Lilly Financials
- 8.5.3.1 Investment in Research and Development
- 8.5.3.2 Eli Lilly Sales Revenue (2018-2022)
- 8.5.3.3 Eli Lilly Market Share (2018-2022)
- 8.5.4 Eli Lilly Recent Developments
- 8.5.5 Eli Lilly Business Strategy
- 8.5.6 Eli Lilly Management Change
- 8.5.7 Eli Lilly SWOT Analysis
- 8.5.7.1 Strength
- 8.5.7.2 Weakness
- 8.5.7.3 Opportunity
- 8.5.7.4 Threats
- 8.5.8 Eli Lilly COVID-19 Impact Analysis
- 8.6 Sunovion
- 8.6.1 Sunovion Company Basic Information, and Sales Area
- 8.6.2 Sunovion Business Segment/ Overview
- 8.6.3 Sunovion Financials
- 8.6.3.1 Investment in Research and Development
- 8.6.3.2 Sunovion Sales Revenue (2018-2022)
- 8.6.3.3 Sunovion Market Share (2018-2022)
- 8.6.4 Sunovion Recent Developments
- 8.6.5 Sunovion Business Strategy
- 8.6.6 Sunovion Management Change
- 8.6.7 Sunovion SWOT Analysis
- 8.6.7.1 Strength
- 8.6.7.2 Weakness
- 8.6.7.3 Opportunity
- 8.6.7.4 Threats
- 8.6.8 Sunovion COVID-19 Impact Analysis
- 8.7 Astrazeneca
- 8.7.1 Astrazeneca Company Basic Information, and Sales Area
- 8.7.2 Astrazeneca Business Segment/ Overview
- 8.7.3 Astrazeneca Financials
- 8.7.3.1 Investment in Research and Development
- 8.7.3.2 Astrazeneca Sales Revenue (2018-2022)
- 8.7.3.3 Astrazeneca Market Share (2018-2022)
- 8.7.4 Astrazeneca Recent Developments
- 8.7.5 Astrazeneca Business Strategy
- 8.7.6 Astrazeneca Management Change
- 8.7.7 Astrazeneca SWOT Analysis
- 8.7.7.1 Strength
- 8.7.7.2 Weakness
- 8.7.7.3 Opportunity
- 8.7.7.4 Threats
- 8.7.8 Astrazeneca COVID-19 Impact Analysis
- 8.8 Actavis Laboratories
- 8.8.1 Actavis Laboratories Company Basic Information, and Sales Area
- 8.8.2 Actavis Laboratories Business Segment/ Overview
- 8.8.3 Actavis Laboratories Financials
- 8.8.3.1 Investment in Research and Development
- 8.8.3.2 Actavis Laboratories Sales Revenue (2018-2022)
- 8.8.3.3 Actavis Laboratories Market Share (2018-2022)
- 8.8.4 Actavis Laboratories Recent Developments
- 8.8.5 Actavis Laboratories Business Strategy
- 8.8.6 Actavis Laboratories Management Change
- 8.8.7 Actavis Laboratories SWOT Analysis
- 8.8.7.1 Strength
- 8.8.7.2 Weakness
- 8.8.7.3 Opportunity
- 8.8.7.4 Threats
- 8.8.8 Actavis Laboratories COVID-19 Impact Analysis
- 8.9 Johnson & Johnson
- 8.9.1 Johnson & Johnson Company Basic Information, and Sales Area
- 8.9.2 Johnson & Johnson Business Segment/ Overview
- 8.9.3 Johnson & Johnson Financials
- 8.9.3.1 Investment in Research and Development
- 8.9.3.2 Johnson & Johnson Sales Revenue (2018-2022)
- 8.9.3.3 Johnson & Johnson Market Share (2018-2022)
- 8.9.4 Johnson & Johnson Recent Developments
- 8.9.5 Johnson & Johnson Business Strategy
- 8.9.6 Johnson & Johnson Management Change
- 8.9.7 Johnson & Johnson SWOT Analysis
- 8.9.7.1 Strength
- 8.9.7.2 Weakness
- 8.9.7.3 Opportunity
- 8.9.7.4 Threats
- 8.9.8 Johnson & Johnson COVID-19 Impact Analysis
- 8.10 Bristol Myers
- 8.10.1 Bristol Myers Company Basic Information, and Sales Area
- 8.10.2 Bristol Myers Business Segment/ Overview
- 8.10.3 Bristol Myers Financials
- 8.10.3.1 Investment in Research and Development
- 8.10.3.2 Bristol Myers Sales Revenue (2018-2022)
- 8.10.3.3 Bristol Myers Market Share (2018-2022)
- 8.10.4 Bristol Myers Recent Developments
- 8.10.5 Bristol Myers Business Strategy
- 8.10.6 Bristol Myers Management Change
- 8.10.7 Bristol Myers SWOT Analysis
- 8.10.7.1 Strength
- 8.10.7.2 Weakness
- 8.10.7.3 Opportunity
- 8.10.7.4 Threats
- 8.10.8 Bristol Myers COVID-19 Impact Analysis
- 8.11 Sage Therapeutics
- 8.11.1 Sage Therapeutics Company Basic Information, and Sales Area
- 8.11.2 Sage Therapeutics Business Segment/ Overview
- 8.11.3 Sage Therapeutics Financials
- 8.11.3.1 Investment in Research and Development
- 8.11.3.2 Sage Therapeutics Sales Revenue (2018-2022)
- 8.11.3.3 Sage Therapeutics Market Share (2018-2022)
- 8.11.4 Sage Therapeutics Recent Developments
- 8.11.5 Sage Therapeutics Business Strategy
- 8.11.6 Sage Therapeutics Management Change
- 8.11.7 Sage Therapeutics SWOT Analysis
- 8.11.7.1 Strength
- 8.11.7.2 Weakness
- 8.11.7.3 Opportunity
- 8.11.7.4 Threats
- 8.11.8 Sage Therapeutics COVID-19 Impact Analysis
- 8.12 Blackthorn Therapeutics
- 8.12.1 Blackthorn Therapeutics Company Basic Information, and Sales Area
- 8.12.2 Blackthorn Therapeutics Business Segment/ Overview
- 8.12.3 Blackthorn Therapeutics Financials
- 8.12.3.1 Investment in Research and Development
- 8.12.3.2 Blackthorn Therapeutics Sales Revenue (2018-2022)
- 8.12.3.3 Blackthorn Therapeutics Market Share (2018-2022)
- 8.12.4 Blackthorn Therapeutics Recent Developments
- 8.12.5 Blackthorn Therapeutics Business Strategy
- 8.12.6 Blackthorn Therapeutics Management Change
- 8.12.7 Blackthorn Therapeutics SWOT Analysis
- 8.12.7.1 Strength
- 8.12.7.2 Weakness
- 8.12.7.3 Opportunity
- 8.12.7.4 Threats
- 8.12.8 Blackthorn Therapeutics COVID-19 Impact Analysis
- 8.13 H Lundbeck A/S
- 8.13.1 H Lundbeck A/S Company Basic Information, and Sales Area
- 8.13.2 H Lundbeck A/S Business Segment/ Overview
- 8.13.3 H Lundbeck A/S Financials
- 8.13.3.1 Investment in Research and Development
- 8.13.3.2 H Lundbeck A/S Sales Revenue (2018-2022)
- 8.13.3.3 H Lundbeck A/S Market Share (2018-2022)
- 8.13.4 H Lundbeck A/S Recent Developments
- 8.13.5 H Lundbeck A/S Business Strategy
- 8.13.6 H Lundbeck A/S Management Change
- 8.13.7 H Lundbeck A/S SWOT Analysis
- 8.13.7.1 Strength
- 8.13.7.2 Weakness
- 8.13.7.3 Opportunity
- 8.13.7.4 Threats
- 8.13.8 H Lundbeck A/S COVID-19 Impact Analysis
- 8.14 Takeda
- 8.14.1 Takeda Company Basic Information, and Sales Area
- 8.14.2 Takeda Business Segment/ Overview
- 8.14.3 Takeda Financials
- 8.14.3.1 Investment in Research and Development
- 8.14.3.2 Takeda Sales Revenue (2018-2022)
- 8.14.3.3 Takeda Market Share (2018-2022)
- 8.14.4 Takeda Recent Developments
- 8.14.5 Takeda Business Strategy
- 8.14.6 Takeda Management Change
- 8.14.7 Takeda SWOT Analysis
- 8.14.7.1 Strength
- 8.14.7.2 Weakness
- 8.14.7.3 Opportunity
- 8.14.7.4 Threats
- 8.14.8 Takeda COVID-19 Impact Analysis
- 8.15 Cerevel Therapeutics Llc
- 8.15.1 Cerevel Therapeutics Llc Company Basic Information, and Sales Area
- 8.15.2 Cerevel Therapeutics Llc Business Segment/ Overview
- 8.15.3 Cerevel Therapeutics Llc Financials
- 8.15.3.1 Investment in Research and Development
- 8.15.3.2 Cerevel Therapeutics Llc Sales Revenue (2018-2022)
- 8.15.3.3 Cerevel Therapeutics Llc Market Share (2018-2022)
- 8.15.4 Cerevel Therapeutics Llc Recent Developments
- 8.15.5 Cerevel Therapeutics Llc Business Strategy
- 8.15.6 Cerevel Therapeutics Llc Management Change
- 8.15.7 Cerevel Therapeutics Llc SWOT Analysis
- 8.15.7.1 Strength
- 8.15.7.2 Weakness
- 8.15.7.3 Opportunity
- 8.15.7.4 Threats
- 8.15.8 Cerevel Therapeutics Llc COVID-19 Impact Analysis
- 9.1 Detailed Qualitative Analysis
- 9.2 Global Neuropsychiatric Drugs Revenue and Share (%) by Drug Type (2018-2030)
- 9.2.1 Typical antipsychotics Market Size
- 9.2.1.1 Global Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 9.2.1.2 Neuropsychiatric Drugs Market for Typical antipsychotics, by Country (2021 Vs 2024)
- 9.2.2 Atypical antipsychotics Market Size
- 9.2.2.1 Global Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 9.2.2.2 Neuropsychiatric Drugs Market for Atypical antipsychotics, by Country (2021 Vs 2024)
- 9.2.1 Typical antipsychotics Market Size
- 10.1 Detailed Qualitative Analysis
- 10.2 Global Neuropsychiatric Drugs Revenue and Share (%) by Indication (2018-2030)
- 10.2.1 Bipolar disorder Market Size
- 10.2.1.1 Global Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 10.2.1.2 Neuropsychiatric Drugs Market for Bipolar disorder, by Country (2021 Vs 2024)
- 10.2.2 Schizophrenia Market Size
- 10.2.2.1 Global Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 10.2.2.2 Neuropsychiatric Drugs Market for Schizophrenia, by Country (2021 Vs 2024)
- 10.2.3 Psychotic depression Market Size
- 10.2.3.1 Global Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 10.2.3.2 Neuropsychiatric Drugs Market for Psychotic depression, by Country (2021 Vs 2024)
- 10.2.4 Others Market Size
- 10.2.4.1 Global Others Market Share and Revenue (USD Million) for 2018-2030
- 10.2.4.2 Neuropsychiatric Drugs Market for Others, by Country (2021 Vs 2024)
- 10.2.1 Bipolar disorder Market Size
- 11.1 Detailed Qualitative Analysis
- 11.2 Global Neuropsychiatric Drugs Revenue and Share (%) by Route of Administration (2018-2030)
- 11.2.1 Parenteral route Market Size
- 11.2.1.1 Global Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 11.2.1.2 Neuropsychiatric Drugs Market for Parenteral route, by Country (2021 Vs 2024)
- 11.2.2 Oral route Market Size
- 11.2.2.1 Global Oral route Market Share and Revenue (USD Million) for 2018-2030
- 11.2.2.2 Neuropsychiatric Drugs Market for Oral route, by Country (2021 Vs 2024)
- 11.2.1 Parenteral route Market Size
- 12.1 Detailed Qualitative Analysis
- 12.2 Global Neuropsychiatric Drugs Market Revenue by Region (2018-2030)
- 12.3 Global Neuropsychiatric Drugs Market Share (%) by Region (2018-2030)
- 13.1 North America
- 13.1.1 North America Neuropsychiatric Drugs Market Trends and Analysis
- 13.1.2 North America Neuropsychiatric Drugs Market by Country, 2018-2030
- 13.1.3 North America Neuropsychiatric Drugs Market Attractiveness Analysis by Country
- 13.2 North America Neuropsychiatric Drugs Market Size (2018-2030)
- 13.2.1 North America Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.2.1.1 Typical antipsychotics
- 13.2.1.1.1 North America Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.2 Atypical antipsychotics
- 13.2.1.2.1 North America Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.1 Typical antipsychotics
- 13.2.2 North America Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 13.2.2.1 Bipolar disorder
- 13.2.2.1.1 North America Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.2 Schizophrenia
- 13.2.2.2.1 North America Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.3 Psychotic depression
- 13.2.2.3.1 North America Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.4 Others
- 13.2.2.4.1 North America Others Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.1 Bipolar disorder
- 13.2.3 North America Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 13.2.3.1 Parenteral route
- 13.2.3.1.1 North America Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 13.2.3.2 Oral route
- 13.2.3.2.1 North America Oral route Market Share and Revenue (USD Million) for 2018-2030
- 13.2.3.1 Parenteral route
- 13.2.1 North America Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.3 United States Neuropsychiatric Drugs Market Size (2018-2030)
- 13.3.1 United States Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.3.1.1 Typical antipsychotics
- 13.3.1.1.1 United States Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.3.1.2 Atypical antipsychotics
- 13.3.1.2.1 United States Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.3.1.1 Typical antipsychotics
- 13.3.2 United States Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 13.3.2.1 Bipolar disorder
- 13.3.2.1.1 United States Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.2 Schizophrenia
- 13.3.2.2.1 United States Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.3 Psychotic depression
- 13.3.2.3.1 United States Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.4 Others
- 13.3.2.4.1 United States Others Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.1 Bipolar disorder
- 13.3.3 United States Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 13.3.3.1 Parenteral route
- 13.3.3.1.1 United States Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 13.3.3.2 Oral route
- 13.3.3.2.1 United States Oral route Market Share and Revenue (USD Million) for 2018-2030
- 13.3.3.1 Parenteral route
- 13.3.1 United States Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.4 Canada Neuropsychiatric Drugs Market Size (2018-2030)
- 13.4.1 Canada Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.4.1.1 Typical antipsychotics
- 13.4.1.1.1 Canada Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.4.1.2 Atypical antipsychotics
- 13.4.1.2.1 Canada Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.4.1.1 Typical antipsychotics
- 13.4.2 Canada Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 13.4.2.1 Bipolar disorder
- 13.4.2.1.1 Canada Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.2 Schizophrenia
- 13.4.2.2.1 Canada Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.3 Psychotic depression
- 13.4.2.3.1 Canada Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.4 Others
- 13.4.2.4.1 Canada Others Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.1 Bipolar disorder
- 13.4.3 Canada Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 13.4.3.1 Parenteral route
- 13.4.3.1.1 Canada Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 13.4.3.2 Oral route
- 13.4.3.2.1 Canada Oral route Market Share and Revenue (USD Million) for 2018-2030
- 13.4.3.1 Parenteral route
- 13.4.1 Canada Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.5 Mexico Neuropsychiatric Drugs Market Size (2018-2030)
- 13.5.1 Mexico Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 13.5.1.1 Typical antipsychotics
- 13.5.1.1.1 Mexico Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.5.1.2 Atypical antipsychotics
- 13.5.1.2.1 Mexico Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 13.5.1.1 Typical antipsychotics
- 13.5.2 Mexico Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 13.5.2.1 Bipolar disorder
- 13.5.2.1.1 Mexico Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.2 Schizophrenia
- 13.5.2.2.1 Mexico Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.3 Psychotic depression
- 13.5.2.3.1 Mexico Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.4 Others
- 13.5.2.4.1 Mexico Others Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.1 Bipolar disorder
- 13.5.3 Mexico Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 13.5.3.1 Parenteral route
- 13.5.3.1.1 Mexico Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 13.5.3.2 Oral route
- 13.5.3.2.1 Mexico Oral route Market Share and Revenue (USD Million) for 2018-2030
- 13.5.3.1 Parenteral route
- 13.5.1 Mexico Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.1 Europe
- 14.1.1 Europe Neuropsychiatric Drugs Market Trends and Analysis
- 14.1.2 Europe Neuropsychiatric Drugs Market by Country, 2018-2030
- 14.1.3 Europe Neuropsychiatric Drugs Market Attractiveness Analysis by Country
- 14.2 Europe Neuropsychiatric Drugs Market Size (2018-2030)
- 14.2.1 Europe Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.2.1.1 Typical antipsychotics
- 14.2.1.1.1 Europe Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.2 Atypical antipsychotics
- 14.2.1.2.1 Europe Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.1 Typical antipsychotics
- 14.2.2 Europe Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.2.2.1 Bipolar disorder
- 14.2.2.1.1 Europe Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.2 Schizophrenia
- 14.2.2.2.1 Europe Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.3 Psychotic depression
- 14.2.2.3.1 Europe Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.4 Others
- 14.2.2.4.1 Europe Others Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.1 Bipolar disorder
- 14.2.3 Europe Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.2.3.1 Parenteral route
- 14.2.3.1.1 Europe Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.2.3.2 Oral route
- 14.2.3.2.1 Europe Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.2.3.1 Parenteral route
- 14.2.1 Europe Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.3 United Kingdom Neuropsychiatric Drugs Market Size (2018-2030)
- 14.3.1 United Kingdom Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.3.1.1 Typical antipsychotics
- 14.3.1.1.1 United Kingdom Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.3.1.2 Atypical antipsychotics
- 14.3.1.2.1 United Kingdom Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.3.1.1 Typical antipsychotics
- 14.3.2 United Kingdom Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.3.2.1 Bipolar disorder
- 14.3.2.1.1 United Kingdom Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.2 Schizophrenia
- 14.3.2.2.1 United Kingdom Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.3 Psychotic depression
- 14.3.2.3.1 United Kingdom Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.4 Others
- 14.3.2.4.1 United Kingdom Others Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.1 Bipolar disorder
- 14.3.3 United Kingdom Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.3.3.1 Parenteral route
- 14.3.3.1.1 United Kingdom Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.3.3.2 Oral route
- 14.3.3.2.1 United Kingdom Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.3.3.1 Parenteral route
- 14.3.1 United Kingdom Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.4 France Neuropsychiatric Drugs Market Size (2018-2030)
- 14.4.1 France Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.4.1.1 Typical antipsychotics
- 14.4.1.1.1 France Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.4.1.2 Atypical antipsychotics
- 14.4.1.2.1 France Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.4.1.1 Typical antipsychotics
- 14.4.2 France Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.4.2.1 Bipolar disorder
- 14.4.2.1.1 France Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.2 Schizophrenia
- 14.4.2.2.1 France Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.3 Psychotic depression
- 14.4.2.3.1 France Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.4 Others
- 14.4.2.4.1 France Others Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.1 Bipolar disorder
- 14.4.3 France Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.4.3.1 Parenteral route
- 14.4.3.1.1 France Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.4.3.2 Oral route
- 14.4.3.2.1 France Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.4.3.1 Parenteral route
- 14.4.1 France Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.5 Germany Neuropsychiatric Drugs Market Size (2018-2030)
- 14.5.1 Germany Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.5.1.1 Typical antipsychotics
- 14.5.1.1.1 Germany Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.5.1.2 Atypical antipsychotics
- 14.5.1.2.1 Germany Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.5.1.1 Typical antipsychotics
- 14.5.2 Germany Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.5.2.1 Bipolar disorder
- 14.5.2.1.1 Germany Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.2 Schizophrenia
- 14.5.2.2.1 Germany Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.3 Psychotic depression
- 14.5.2.3.1 Germany Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.4 Others
- 14.5.2.4.1 Germany Others Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.1 Bipolar disorder
- 14.5.3 Germany Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.5.3.1 Parenteral route
- 14.5.3.1.1 Germany Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.5.3.2 Oral route
- 14.5.3.2.1 Germany Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.5.3.1 Parenteral route
- 14.5.1 Germany Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.6 Italy Neuropsychiatric Drugs Market Size (2018-2030)
- 14.6.1 Italy Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.6.1.1 Typical antipsychotics
- 14.6.1.1.1 Italy Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.6.1.2 Atypical antipsychotics
- 14.6.1.2.1 Italy Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.6.1.1 Typical antipsychotics
- 14.6.2 Italy Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.6.2.1 Bipolar disorder
- 14.6.2.1.1 Italy Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.2 Schizophrenia
- 14.6.2.2.1 Italy Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.3 Psychotic depression
- 14.6.2.3.1 Italy Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.4 Others
- 14.6.2.4.1 Italy Others Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.1 Bipolar disorder
- 14.6.3 Italy Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.6.3.1 Parenteral route
- 14.6.3.1.1 Italy Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.6.3.2 Oral route
- 14.6.3.2.1 Italy Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.6.3.1 Parenteral route
- 14.6.1 Italy Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.7 Russia Neuropsychiatric Drugs Market Size (2018-2030)
- 14.7.1 Russia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.7.1.1 Typical antipsychotics
- 14.7.1.1.1 Russia Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.7.1.2 Atypical antipsychotics
- 14.7.1.2.1 Russia Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.7.1.1 Typical antipsychotics
- 14.7.2 Russia Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.7.2.1 Bipolar disorder
- 14.7.2.1.1 Russia Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.2 Schizophrenia
- 14.7.2.2.1 Russia Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.3 Psychotic depression
- 14.7.2.3.1 Russia Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.4 Others
- 14.7.2.4.1 Russia Others Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.1 Bipolar disorder
- 14.7.3 Russia Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.7.3.1 Parenteral route
- 14.7.3.1.1 Russia Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.7.3.2 Oral route
- 14.7.3.2.1 Russia Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.7.3.1 Parenteral route
- 14.7.1 Russia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.8 Spain Neuropsychiatric Drugs Market Size (2018-2030)
- 14.8.1 Spain Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.8.1.1 Typical antipsychotics
- 14.8.1.1.1 Spain Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.8.1.2 Atypical antipsychotics
- 14.8.1.2.1 Spain Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.8.1.1 Typical antipsychotics
- 14.8.2 Spain Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.8.2.1 Bipolar disorder
- 14.8.2.1.1 Spain Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.2 Schizophrenia
- 14.8.2.2.1 Spain Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.3 Psychotic depression
- 14.8.2.3.1 Spain Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.4 Others
- 14.8.2.4.1 Spain Others Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.1 Bipolar disorder
- 14.8.3 Spain Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.8.3.1 Parenteral route
- 14.8.3.1.1 Spain Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.8.3.2 Oral route
- 14.8.3.2.1 Spain Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.8.3.1 Parenteral route
- 14.8.1 Spain Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.9 Sweden Neuropsychiatric Drugs Market Size (2018-2030)
- 14.9.1 Sweden Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.9.1.1 Typical antipsychotics
- 14.9.1.1.1 Sweden Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.9.1.2 Atypical antipsychotics
- 14.9.1.2.1 Sweden Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.9.1.1 Typical antipsychotics
- 14.9.2 Sweden Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.9.2.1 Bipolar disorder
- 14.9.2.1.1 Sweden Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.2 Schizophrenia
- 14.9.2.2.1 Sweden Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.3 Psychotic depression
- 14.9.2.3.1 Sweden Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.4 Others
- 14.9.2.4.1 Sweden Others Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.1 Bipolar disorder
- 14.9.3 Sweden Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.9.3.1 Parenteral route
- 14.9.3.1.1 Sweden Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.9.3.2 Oral route
- 14.9.3.2.1 Sweden Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.9.3.1 Parenteral route
- 14.9.1 Sweden Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.10 Denmark Neuropsychiatric Drugs Market Size (2018-2030)
- 14.10.1 Denmark Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.10.1.1 Typical antipsychotics
- 14.10.1.1.1 Denmark Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.10.1.2 Atypical antipsychotics
- 14.10.1.2.1 Denmark Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.10.1.1 Typical antipsychotics
- 14.10.2 Denmark Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.10.2.1 Bipolar disorder
- 14.10.2.1.1 Denmark Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.2 Schizophrenia
- 14.10.2.2.1 Denmark Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.3 Psychotic depression
- 14.10.2.3.1 Denmark Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.4 Others
- 14.10.2.4.1 Denmark Others Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.1 Bipolar disorder
- 14.10.3 Denmark Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.10.3.1 Parenteral route
- 14.10.3.1.1 Denmark Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.10.3.2 Oral route
- 14.10.3.2.1 Denmark Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.10.3.1 Parenteral route
- 14.10.1 Denmark Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.11 Netherlands Neuropsychiatric Drugs Market Size (2018-2030)
- 14.11.1 Netherlands Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.11.1.1 Typical antipsychotics
- 14.11.1.1.1 Netherlands Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.11.1.2 Atypical antipsychotics
- 14.11.1.2.1 Netherlands Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.11.1.1 Typical antipsychotics
- 14.11.2 Netherlands Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.11.2.1 Bipolar disorder
- 14.11.2.1.1 Netherlands Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.2 Schizophrenia
- 14.11.2.2.1 Netherlands Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.3 Psychotic depression
- 14.11.2.3.1 Netherlands Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.4 Others
- 14.11.2.4.1 Netherlands Others Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.1 Bipolar disorder
- 14.11.3 Netherlands Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.11.3.1 Parenteral route
- 14.11.3.1.1 Netherlands Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.11.3.2 Oral route
- 14.11.3.2.1 Netherlands Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.11.3.1 Parenteral route
- 14.11.1 Netherlands Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.12 Switzerland Neuropsychiatric Drugs Market Size (2018-2030)
- 14.12.1 Switzerland Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.12.1.1 Typical antipsychotics
- 14.12.1.1.1 Switzerland Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.12.1.2 Atypical antipsychotics
- 14.12.1.2.1 Switzerland Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.12.1.1 Typical antipsychotics
- 14.12.2 Switzerland Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.12.2.1 Bipolar disorder
- 14.12.2.1.1 Switzerland Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.2 Schizophrenia
- 14.12.2.2.1 Switzerland Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.3 Psychotic depression
- 14.12.2.3.1 Switzerland Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.4 Others
- 14.12.2.4.1 Switzerland Others Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.1 Bipolar disorder
- 14.12.3 Switzerland Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.12.3.1 Parenteral route
- 14.12.3.1.1 Switzerland Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.12.3.2 Oral route
- 14.12.3.2.1 Switzerland Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.12.3.1 Parenteral route
- 14.12.1 Switzerland Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.13 Belgium Neuropsychiatric Drugs Market Size (2018-2030)
- 14.13.1 Belgium Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 14.13.1.1 Typical antipsychotics
- 14.13.1.1.1 Belgium Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.13.1.2 Atypical antipsychotics
- 14.13.1.2.1 Belgium Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 14.13.1.1 Typical antipsychotics
- 14.13.2 Belgium Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 14.13.2.1 Bipolar disorder
- 14.13.2.1.1 Belgium Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.2 Schizophrenia
- 14.13.2.2.1 Belgium Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.3 Psychotic depression
- 14.13.2.3.1 Belgium Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.4 Others
- 14.13.2.4.1 Belgium Others Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.1 Bipolar disorder
- 14.13.3 Belgium Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 14.13.3.1 Parenteral route
- 14.13.3.1.1 Belgium Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 14.13.3.2 Oral route
- 14.13.3.2.1 Belgium Oral route Market Share and Revenue (USD Million) for 2018-2030
- 14.13.3.1 Parenteral route
- 14.13.1 Belgium Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.1 Asia Pacific
- 15.1.1 Asia Pacific Neuropsychiatric Drugs Market Trends and Analysis
- 15.1.2 Asia Pacific Neuropsychiatric Drugs Market by Country, 2018-2030
- 15.1.3 Asia Pacific Neuropsychiatric Drugs Market Attractiveness Analysis by Country
- 15.2 Asia Pacific Neuropsychiatric Drugs Market Size (2018-2030)
- 15.2.1 Asia Pacific Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.2.1.1 Typical antipsychotics
- 15.2.1.1.1 Asia Pacific Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.2 Atypical antipsychotics
- 15.2.1.2.1 Asia Pacific Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.1 Typical antipsychotics
- 15.2.2 Asia Pacific Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.2.2.1 Bipolar disorder
- 15.2.2.1.1 Asia Pacific Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.2 Schizophrenia
- 15.2.2.2.1 Asia Pacific Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.3 Psychotic depression
- 15.2.2.3.1 Asia Pacific Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.4 Others
- 15.2.2.4.1 Asia Pacific Others Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.1 Bipolar disorder
- 15.2.3 Asia Pacific Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.2.3.1 Parenteral route
- 15.2.3.1.1 Asia Pacific Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.2.3.2 Oral route
- 15.2.3.2.1 Asia Pacific Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.2.3.1 Parenteral route
- 15.2.1 Asia Pacific Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.3 China Neuropsychiatric Drugs Market Size (2018-2030)
- 15.3.1 China Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.3.1.1 Typical antipsychotics
- 15.3.1.1.1 China Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.3.1.2 Atypical antipsychotics
- 15.3.1.2.1 China Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.3.1.1 Typical antipsychotics
- 15.3.2 China Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.3.2.1 Bipolar disorder
- 15.3.2.1.1 China Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.2 Schizophrenia
- 15.3.2.2.1 China Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.3 Psychotic depression
- 15.3.2.3.1 China Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.4 Others
- 15.3.2.4.1 China Others Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.1 Bipolar disorder
- 15.3.3 China Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.3.3.1 Parenteral route
- 15.3.3.1.1 China Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.3.3.2 Oral route
- 15.3.3.2.1 China Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.3.3.1 Parenteral route
- 15.3.1 China Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.4 Japan Neuropsychiatric Drugs Market Size (2018-2030)
- 15.4.1 Japan Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.4.1.1 Typical antipsychotics
- 15.4.1.1.1 Japan Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.4.1.2 Atypical antipsychotics
- 15.4.1.2.1 Japan Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.4.1.1 Typical antipsychotics
- 15.4.2 Japan Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.4.2.1 Bipolar disorder
- 15.4.2.1.1 Japan Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.2 Schizophrenia
- 15.4.2.2.1 Japan Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.3 Psychotic depression
- 15.4.2.3.1 Japan Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.4 Others
- 15.4.2.4.1 Japan Others Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.1 Bipolar disorder
- 15.4.3 Japan Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.4.3.1 Parenteral route
- 15.4.3.1.1 Japan Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.4.3.2 Oral route
- 15.4.3.2.1 Japan Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.4.3.1 Parenteral route
- 15.4.1 Japan Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.5 Korea Neuropsychiatric Drugs Market Size (2018-2030)
- 15.5.1 Korea Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.5.1.1 Typical antipsychotics
- 15.5.1.1.1 Korea Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.5.1.2 Atypical antipsychotics
- 15.5.1.2.1 Korea Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.5.1.1 Typical antipsychotics
- 15.5.2 Korea Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.5.2.1 Bipolar disorder
- 15.5.2.1.1 Korea Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.2 Schizophrenia
- 15.5.2.2.1 Korea Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.3 Psychotic depression
- 15.5.2.3.1 Korea Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.4 Others
- 15.5.2.4.1 Korea Others Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.1 Bipolar disorder
- 15.5.3 Korea Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.5.3.1 Parenteral route
- 15.5.3.1.1 Korea Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.5.3.2 Oral route
- 15.5.3.2.1 Korea Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.5.3.1 Parenteral route
- 15.5.1 Korea Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.6 India Neuropsychiatric Drugs Market Size (2018-2030)
- 15.6.1 India Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.6.1.1 Typical antipsychotics
- 15.6.1.1.1 India Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.6.1.2 Atypical antipsychotics
- 15.6.1.2.1 India Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.6.1.1 Typical antipsychotics
- 15.6.2 India Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.6.2.1 Bipolar disorder
- 15.6.2.1.1 India Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.2 Schizophrenia
- 15.6.2.2.1 India Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.3 Psychotic depression
- 15.6.2.3.1 India Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.4 Others
- 15.6.2.4.1 India Others Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.1 Bipolar disorder
- 15.6.3 India Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.6.3.1 Parenteral route
- 15.6.3.1.1 India Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.6.3.2 Oral route
- 15.6.3.2.1 India Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.6.3.1 Parenteral route
- 15.6.1 India Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.7 Australia Neuropsychiatric Drugs Market Size (2018-2030)
- 15.7.1 Australia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.7.1.1 Typical antipsychotics
- 15.7.1.1.1 Australia Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.7.1.2 Atypical antipsychotics
- 15.7.1.2.1 Australia Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.7.1.1 Typical antipsychotics
- 15.7.2 Australia Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.7.2.1 Bipolar disorder
- 15.7.2.1.1 Australia Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.2 Schizophrenia
- 15.7.2.2.1 Australia Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.3 Psychotic depression
- 15.7.2.3.1 Australia Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.4 Others
- 15.7.2.4.1 Australia Others Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.1 Bipolar disorder
- 15.7.3 Australia Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.7.3.1 Parenteral route
- 15.7.3.1.1 Australia Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.7.3.2 Oral route
- 15.7.3.2.1 Australia Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.7.3.1 Parenteral route
- 15.7.1 Australia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.8 Philippines Neuropsychiatric Drugs Market Size (2018-2030)
- 15.8.1 Philippines Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.8.1.1 Typical antipsychotics
- 15.8.1.1.1 Philippines Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.8.1.2 Atypical antipsychotics
- 15.8.1.2.1 Philippines Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.8.1.1 Typical antipsychotics
- 15.8.2 Philippines Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.8.2.1 Bipolar disorder
- 15.8.2.1.1 Philippines Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.2 Schizophrenia
- 15.8.2.2.1 Philippines Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.3 Psychotic depression
- 15.8.2.3.1 Philippines Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.4 Others
- 15.8.2.4.1 Philippines Others Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.1 Bipolar disorder
- 15.8.3 Philippines Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.8.3.1 Parenteral route
- 15.8.3.1.1 Philippines Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.8.3.2 Oral route
- 15.8.3.2.1 Philippines Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.8.3.1 Parenteral route
- 15.8.1 Philippines Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.9 Singapore Neuropsychiatric Drugs Market Size (2018-2030)
- 15.9.1 Singapore Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.9.1.1 Typical antipsychotics
- 15.9.1.1.1 Singapore Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.9.1.2 Atypical antipsychotics
- 15.9.1.2.1 Singapore Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.9.1.1 Typical antipsychotics
- 15.9.2 Singapore Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.9.2.1 Bipolar disorder
- 15.9.2.1.1 Singapore Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.2 Schizophrenia
- 15.9.2.2.1 Singapore Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.3 Psychotic depression
- 15.9.2.3.1 Singapore Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.4 Others
- 15.9.2.4.1 Singapore Others Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.1 Bipolar disorder
- 15.9.3 Singapore Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.9.3.1 Parenteral route
- 15.9.3.1.1 Singapore Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.9.3.2 Oral route
- 15.9.3.2.1 Singapore Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.9.3.1 Parenteral route
- 15.9.1 Singapore Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.10 Malaysia Neuropsychiatric Drugs Market Size (2018-2030)
- 15.10.1 Malaysia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.10.1.1 Typical antipsychotics
- 15.10.1.1.1 Malaysia Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.10.1.2 Atypical antipsychotics
- 15.10.1.2.1 Malaysia Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.10.1.1 Typical antipsychotics
- 15.10.2 Malaysia Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.10.2.1 Bipolar disorder
- 15.10.2.1.1 Malaysia Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.2 Schizophrenia
- 15.10.2.2.1 Malaysia Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.3 Psychotic depression
- 15.10.2.3.1 Malaysia Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.4 Others
- 15.10.2.4.1 Malaysia Others Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.1 Bipolar disorder
- 15.10.3 Malaysia Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.10.3.1 Parenteral route
- 15.10.3.1.1 Malaysia Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.10.3.2 Oral route
- 15.10.3.2.1 Malaysia Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.10.3.1 Parenteral route
- 15.10.1 Malaysia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.11 Thailand Neuropsychiatric Drugs Market Size (2018-2030)
- 15.11.1 Thailand Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.11.1.1 Typical antipsychotics
- 15.11.1.1.1 Thailand Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.11.1.2 Atypical antipsychotics
- 15.11.1.2.1 Thailand Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.11.1.1 Typical antipsychotics
- 15.11.2 Thailand Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.11.2.1 Bipolar disorder
- 15.11.2.1.1 Thailand Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.2 Schizophrenia
- 15.11.2.2.1 Thailand Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.3 Psychotic depression
- 15.11.2.3.1 Thailand Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.4 Others
- 15.11.2.4.1 Thailand Others Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.1 Bipolar disorder
- 15.11.3 Thailand Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.11.3.1 Parenteral route
- 15.11.3.1.1 Thailand Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.11.3.2 Oral route
- 15.11.3.2.1 Thailand Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.11.3.1 Parenteral route
- 15.11.1 Thailand Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.12 Indonesia Neuropsychiatric Drugs Market Size (2018-2030)
- 15.12.1 Indonesia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.12.1.1 Typical antipsychotics
- 15.12.1.1.1 Indonesia Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.12.1.2 Atypical antipsychotics
- 15.12.1.2.1 Indonesia Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.12.1.1 Typical antipsychotics
- 15.12.2 Indonesia Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.12.2.1 Bipolar disorder
- 15.12.2.1.1 Indonesia Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.2 Schizophrenia
- 15.12.2.2.1 Indonesia Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.3 Psychotic depression
- 15.12.2.3.1 Indonesia Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.4 Others
- 15.12.2.4.1 Indonesia Others Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.1 Bipolar disorder
- 15.12.3 Indonesia Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.12.3.1 Parenteral route
- 15.12.3.1.1 Indonesia Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.12.3.2 Oral route
- 15.12.3.2.1 Indonesia Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.12.3.1 Parenteral route
- 15.12.1 Indonesia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.13 Rest of APAC Neuropsychiatric Drugs Market Size (2018-2030)
- 15.13.1 Rest of APAC Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 15.13.1.1 Typical antipsychotics
- 15.13.1.1.1 Rest of APAC Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.13.1.2 Atypical antipsychotics
- 15.13.1.2.1 Rest of APAC Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 15.13.1.1 Typical antipsychotics
- 15.13.2 Rest of APAC Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 15.13.2.1 Bipolar disorder
- 15.13.2.1.1 Rest of APAC Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.2 Schizophrenia
- 15.13.2.2.1 Rest of APAC Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.3 Psychotic depression
- 15.13.2.3.1 Rest of APAC Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.4 Others
- 15.13.2.4.1 Rest of APAC Others Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.1 Bipolar disorder
- 15.13.3 Rest of APAC Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 15.13.3.1 Parenteral route
- 15.13.3.1.1 Rest of APAC Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 15.13.3.2 Oral route
- 15.13.3.2.1 Rest of APAC Oral route Market Share and Revenue (USD Million) for 2018-2030
- 15.13.3.1 Parenteral route
- 15.13.1 Rest of APAC Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.1 Latin America
- 16.1.1 Latin America Neuropsychiatric Drugs Market Trends and Analysis
- 16.1.2 Latin America Neuropsychiatric Drugs Market by Country, 2018-2030
- 16.1.3 Latin America Neuropsychiatric Drugs Market Attractiveness Analysis by Country
- 16.2 Latin America Neuropsychiatric Drugs Market Size (2018-2030)
- 16.2.1 Latin America Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.2.1.1 Typical antipsychotics
- 16.2.1.1.1 Latin America Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.2 Atypical antipsychotics
- 16.2.1.2.1 Latin America Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.1 Typical antipsychotics
- 16.2.2 Latin America Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 16.2.2.1 Bipolar disorder
- 16.2.2.1.1 Latin America Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.2 Schizophrenia
- 16.2.2.2.1 Latin America Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.3 Psychotic depression
- 16.2.2.3.1 Latin America Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.4 Others
- 16.2.2.4.1 Latin America Others Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.1 Bipolar disorder
- 16.2.3 Latin America Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 16.2.3.1 Parenteral route
- 16.2.3.1.1 Latin America Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 16.2.3.2 Oral route
- 16.2.3.2.1 Latin America Oral route Market Share and Revenue (USD Million) for 2018-2030
- 16.2.3.1 Parenteral route
- 16.2.1 Latin America Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.3 Brazil Neuropsychiatric Drugs Market Size (2018-2030)
- 16.3.1 Brazil Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.3.1.1 Typical antipsychotics
- 16.3.1.1.1 Brazil Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.3.1.2 Atypical antipsychotics
- 16.3.1.2.1 Brazil Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.3.1.1 Typical antipsychotics
- 16.3.2 Brazil Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 16.3.2.1 Bipolar disorder
- 16.3.2.1.1 Brazil Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.2 Schizophrenia
- 16.3.2.2.1 Brazil Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.3 Psychotic depression
- 16.3.2.3.1 Brazil Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.4 Others
- 16.3.2.4.1 Brazil Others Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.1 Bipolar disorder
- 16.3.3 Brazil Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 16.3.3.1 Parenteral route
- 16.3.3.1.1 Brazil Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 16.3.3.2 Oral route
- 16.3.3.2.1 Brazil Oral route Market Share and Revenue (USD Million) for 2018-2030
- 16.3.3.1 Parenteral route
- 16.3.1 Brazil Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.4 Argentina Neuropsychiatric Drugs Market Size (2018-2030)
- 16.4.1 Argentina Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.4.1.1 Typical antipsychotics
- 16.4.1.1.1 Argentina Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.4.1.2 Atypical antipsychotics
- 16.4.1.2.1 Argentina Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.4.1.1 Typical antipsychotics
- 16.4.2 Argentina Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 16.4.2.1 Bipolar disorder
- 16.4.2.1.1 Argentina Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.2 Schizophrenia
- 16.4.2.2.1 Argentina Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.3 Psychotic depression
- 16.4.2.3.1 Argentina Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.4 Others
- 16.4.2.4.1 Argentina Others Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.1 Bipolar disorder
- 16.4.3 Argentina Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 16.4.3.1 Parenteral route
- 16.4.3.1.1 Argentina Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 16.4.3.2 Oral route
- 16.4.3.2.1 Argentina Oral route Market Share and Revenue (USD Million) for 2018-2030
- 16.4.3.1 Parenteral route
- 16.4.1 Argentina Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.5 Colombia Neuropsychiatric Drugs Market Size (2018-2030)
- 16.5.1 Colombia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.5.1.1 Typical antipsychotics
- 16.5.1.1.1 Colombia Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.5.1.2 Atypical antipsychotics
- 16.5.1.2.1 Colombia Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.5.1.1 Typical antipsychotics
- 16.5.2 Colombia Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 16.5.2.1 Bipolar disorder
- 16.5.2.1.1 Colombia Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.2 Schizophrenia
- 16.5.2.2.1 Colombia Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.3 Psychotic depression
- 16.5.2.3.1 Colombia Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.4 Others
- 16.5.2.4.1 Colombia Others Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.1 Bipolar disorder
- 16.5.3 Colombia Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 16.5.3.1 Parenteral route
- 16.5.3.1.1 Colombia Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 16.5.3.2 Oral route
- 16.5.3.2.1 Colombia Oral route Market Share and Revenue (USD Million) for 2018-2030
- 16.5.3.1 Parenteral route
- 16.5.1 Colombia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.6 Peru Neuropsychiatric Drugs Market Size (2018-2030)
- 16.6.1 Peru Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.6.1.1 Typical antipsychotics
- 16.6.1.1.1 Peru Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.6.1.2 Atypical antipsychotics
- 16.6.1.2.1 Peru Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.6.1.1 Typical antipsychotics
- 16.6.2 Peru Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 16.6.2.1 Bipolar disorder
- 16.6.2.1.1 Peru Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.2 Schizophrenia
- 16.6.2.2.1 Peru Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.3 Psychotic depression
- 16.6.2.3.1 Peru Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.4 Others
- 16.6.2.4.1 Peru Others Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.1 Bipolar disorder
- 16.6.3 Peru Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 16.6.3.1 Parenteral route
- 16.6.3.1.1 Peru Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 16.6.3.2 Oral route
- 16.6.3.2.1 Peru Oral route Market Share and Revenue (USD Million) for 2018-2030
- 16.6.3.1 Parenteral route
- 16.6.1 Peru Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.7 Chile Neuropsychiatric Drugs Market Size (2018-2030)
- 16.7.1 Chile Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.7.1.1 Typical antipsychotics
- 16.7.1.1.1 Chile Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.7.1.2 Atypical antipsychotics
- 16.7.1.2.1 Chile Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.7.1.1 Typical antipsychotics
- 16.7.2 Chile Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 16.7.2.1 Bipolar disorder
- 16.7.2.1.1 Chile Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.2 Schizophrenia
- 16.7.2.2.1 Chile Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.3 Psychotic depression
- 16.7.2.3.1 Chile Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.4 Others
- 16.7.2.4.1 Chile Others Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.1 Bipolar disorder
- 16.7.3 Chile Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 16.7.3.1 Parenteral route
- 16.7.3.1.1 Chile Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 16.7.3.2 Oral route
- 16.7.3.2.1 Chile Oral route Market Share and Revenue (USD Million) for 2018-2030
- 16.7.3.1 Parenteral route
- 16.7.1 Chile Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.8 Rest of South America Neuropsychiatric Drugs Market Size (2018-2030)
- 16.8.1 Rest of South America Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 16.8.1.1 Typical antipsychotics
- 16.8.1.1.1 Rest of South America Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.8.1.2 Atypical antipsychotics
- 16.8.1.2.1 Rest of South America Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 16.8.1.1 Typical antipsychotics
- 16.8.2 Rest of South America Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 16.8.2.1 Bipolar disorder
- 16.8.2.1.1 Rest of South America Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.2 Schizophrenia
- 16.8.2.2.1 Rest of South America Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.3 Psychotic depression
- 16.8.2.3.1 Rest of South America Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.4 Others
- 16.8.2.4.1 Rest of South America Others Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.1 Bipolar disorder
- 16.8.3 Rest of South America Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 16.8.3.1 Parenteral route
- 16.8.3.1.1 Rest of South America Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 16.8.3.2 Oral route
- 16.8.3.2.1 Rest of South America Oral route Market Share and Revenue (USD Million) for 2018-2030
- 16.8.3.1 Parenteral route
- 16.8.1 Rest of South America Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.1 Middle East and Africa
- 17.1.1 Middle East and Africa Neuropsychiatric Drugs Market Trends and Analysis
- 17.1.2 Middle East and Africa Neuropsychiatric Drugs Market by Country, 2018-2030
- 17.1.3 Middle East and Africa Neuropsychiatric Drugs Market Attractiveness Analysis by Country
- 17.2 Middle East and Africa Neuropsychiatric Drugs Market Size (2018-2030)
- 17.2.1 Middle East and Africa Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.2.1.1 Typical antipsychotics
- 17.2.1.1.1 Middle East and Africa Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.2 Atypical antipsychotics
- 17.2.1.2.1 Middle East and Africa Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.1 Typical antipsychotics
- 17.2.2 Middle East and Africa Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.2.2.1 Bipolar disorder
- 17.2.2.1.1 Middle East and Africa Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.2 Schizophrenia
- 17.2.2.2.1 Middle East and Africa Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.3 Psychotic depression
- 17.2.2.3.1 Middle East and Africa Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.4 Others
- 17.2.2.4.1 Middle East and Africa Others Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.1 Bipolar disorder
- 17.2.3 Middle East and Africa Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.2.3.1 Parenteral route
- 17.2.3.1.1 Middle East and Africa Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.2.3.2 Oral route
- 17.2.3.2.1 Middle East and Africa Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.2.3.1 Parenteral route
- 17.2.1 Middle East and Africa Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.3 Saudi Arabia Neuropsychiatric Drugs Market Size (2018-2030)
- 17.3.1 Saudi Arabia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.3.1.1 Typical antipsychotics
- 17.3.1.1.1 Saudi Arabia Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.3.1.2 Atypical antipsychotics
- 17.3.1.2.1 Saudi Arabia Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.3.1.1 Typical antipsychotics
- 17.3.2 Saudi Arabia Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.3.2.1 Bipolar disorder
- 17.3.2.1.1 Saudi Arabia Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.2 Schizophrenia
- 17.3.2.2.1 Saudi Arabia Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.3 Psychotic depression
- 17.3.2.3.1 Saudi Arabia Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.4 Others
- 17.3.2.4.1 Saudi Arabia Others Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.1 Bipolar disorder
- 17.3.3 Saudi Arabia Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.3.3.1 Parenteral route
- 17.3.3.1.1 Saudi Arabia Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.3.3.2 Oral route
- 17.3.3.2.1 Saudi Arabia Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.3.3.1 Parenteral route
- 17.3.1 Saudi Arabia Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.4 Turkey Neuropsychiatric Drugs Market Size (2018-2030)
- 17.4.1 Turkey Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.4.1.1 Typical antipsychotics
- 17.4.1.1.1 Turkey Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.4.1.2 Atypical antipsychotics
- 17.4.1.2.1 Turkey Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.4.1.1 Typical antipsychotics
- 17.4.2 Turkey Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.4.2.1 Bipolar disorder
- 17.4.2.1.1 Turkey Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.2 Schizophrenia
- 17.4.2.2.1 Turkey Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.3 Psychotic depression
- 17.4.2.3.1 Turkey Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.4 Others
- 17.4.2.4.1 Turkey Others Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.1 Bipolar disorder
- 17.4.3 Turkey Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.4.3.1 Parenteral route
- 17.4.3.1.1 Turkey Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.4.3.2 Oral route
- 17.4.3.2.1 Turkey Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.4.3.1 Parenteral route
- 17.4.1 Turkey Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.5 Nigeria Neuropsychiatric Drugs Market Size (2018-2030)
- 17.5.1 Nigeria Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.5.1.1 Typical antipsychotics
- 17.5.1.1.1 Nigeria Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.5.1.2 Atypical antipsychotics
- 17.5.1.2.1 Nigeria Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.5.1.1 Typical antipsychotics
- 17.5.2 Nigeria Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.5.2.1 Bipolar disorder
- 17.5.2.1.1 Nigeria Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.2 Schizophrenia
- 17.5.2.2.1 Nigeria Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.3 Psychotic depression
- 17.5.2.3.1 Nigeria Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.4 Others
- 17.5.2.4.1 Nigeria Others Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.1 Bipolar disorder
- 17.5.3 Nigeria Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.5.3.1 Parenteral route
- 17.5.3.1.1 Nigeria Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.5.3.2 Oral route
- 17.5.3.2.1 Nigeria Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.5.3.1 Parenteral route
- 17.5.1 Nigeria Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.6 UAE Neuropsychiatric Drugs Market Size (2018-2030)
- 17.6.1 UAE Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.6.1.1 Typical antipsychotics
- 17.6.1.1.1 UAE Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.6.1.2 Atypical antipsychotics
- 17.6.1.2.1 UAE Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.6.1.1 Typical antipsychotics
- 17.6.2 UAE Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.6.2.1 Bipolar disorder
- 17.6.2.1.1 UAE Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.2 Schizophrenia
- 17.6.2.2.1 UAE Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.3 Psychotic depression
- 17.6.2.3.1 UAE Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.4 Others
- 17.6.2.4.1 UAE Others Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.1 Bipolar disorder
- 17.6.3 UAE Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.6.3.1 Parenteral route
- 17.6.3.1.1 UAE Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.6.3.2 Oral route
- 17.6.3.2.1 UAE Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.6.3.1 Parenteral route
- 17.6.1 UAE Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.7 Egypt Neuropsychiatric Drugs Market Size (2018-2030)
- 17.7.1 Egypt Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.7.1.1 Typical antipsychotics
- 17.7.1.1.1 Egypt Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.7.1.2 Atypical antipsychotics
- 17.7.1.2.1 Egypt Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.7.1.1 Typical antipsychotics
- 17.7.2 Egypt Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.7.2.1 Bipolar disorder
- 17.7.2.1.1 Egypt Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.2 Schizophrenia
- 17.7.2.2.1 Egypt Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.3 Psychotic depression
- 17.7.2.3.1 Egypt Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.4 Others
- 17.7.2.4.1 Egypt Others Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.1 Bipolar disorder
- 17.7.3 Egypt Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.7.3.1 Parenteral route
- 17.7.3.1.1 Egypt Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.7.3.2 Oral route
- 17.7.3.2.1 Egypt Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.7.3.1 Parenteral route
- 17.7.1 Egypt Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.8 South Africa Neuropsychiatric Drugs Market Size (2018-2030)
- 17.8.1 South Africa Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.8.1.1 Typical antipsychotics
- 17.8.1.1.1 South Africa Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.8.1.2 Atypical antipsychotics
- 17.8.1.2.1 South Africa Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.8.1.1 Typical antipsychotics
- 17.8.2 South Africa Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.8.2.1 Bipolar disorder
- 17.8.2.1.1 South Africa Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.2 Schizophrenia
- 17.8.2.2.1 South Africa Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.3 Psychotic depression
- 17.8.2.3.1 South Africa Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.4 Others
- 17.8.2.4.1 South Africa Others Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.1 Bipolar disorder
- 17.8.3 South Africa Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.8.3.1 Parenteral route
- 17.8.3.1.1 South Africa Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.8.3.2 Oral route
- 17.8.3.2.1 South Africa Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.8.3.1 Parenteral route
- 17.8.1 South Africa Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.9 GCC Countries Neuropsychiatric Drugs Market Size (2018-2030)
- 17.9.1 GCC Countries Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.9.1.1 Typical antipsychotics
- 17.9.1.1.1 GCC Countries Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.9.1.2 Atypical antipsychotics
- 17.9.1.2.1 GCC Countries Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.9.1.1 Typical antipsychotics
- 17.9.2 GCC Countries Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.9.2.1 Bipolar disorder
- 17.9.2.1.1 GCC Countries Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.2 Schizophrenia
- 17.9.2.2.1 GCC Countries Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.3 Psychotic depression
- 17.9.2.3.1 GCC Countries Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.4 Others
- 17.9.2.4.1 GCC Countries Others Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.1 Bipolar disorder
- 17.9.3 GCC Countries Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.9.3.1 Parenteral route
- 17.9.3.1.1 GCC Countries Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.9.3.2 Oral route
- 17.9.3.2.1 GCC Countries Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.9.3.1 Parenteral route
- 17.9.1 GCC Countries Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.10 Rest of MEA Neuropsychiatric Drugs Market Size (2018-2030)
- 17.10.1 Rest of MEA Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 17.10.1.1 Typical antipsychotics
- 17.10.1.1.1 Rest of MEA Typical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.10.1.2 Atypical antipsychotics
- 17.10.1.2.1 Rest of MEA Atypical antipsychotics Market Share and Revenue (USD Million) for 2018-2030
- 17.10.1.1 Typical antipsychotics
- 17.10.2 Rest of MEA Neuropsychiatric Drugs Market (USD Million) by Indication (2018-2030)
- 17.10.2.1 Bipolar disorder
- 17.10.2.1.1 Rest of MEA Bipolar disorder Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.2 Schizophrenia
- 17.10.2.2.1 Rest of MEA Schizophrenia Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.3 Psychotic depression
- 17.10.2.3.1 Rest of MEA Psychotic depression Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.4 Others
- 17.10.2.4.1 Rest of MEA Others Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.1 Bipolar disorder
- 17.10.3 Rest of MEA Neuropsychiatric Drugs Market (USD Million) by Route of Administration (2018-2030)
- 17.10.3.1 Parenteral route
- 17.10.3.1.1 Rest of MEA Parenteral route Market Share and Revenue (USD Million) for 2018-2030
- 17.10.3.2 Oral route
- 17.10.3.2.1 Rest of MEA Oral route Market Share and Revenue (USD Million) for 2018-2030
- 17.10.3.1 Parenteral route
- 17.10.1 Rest of MEA Neuropsychiatric Drugs Market (USD Million) by Drug Type (2018-2030)
- 18.1 Key Takeaways
- 18.2 Analyst Point of View
Segmentation Level Customization | |
Global level Data Customization | |
Region level Data Customization | |
Country level Data Customization | |
Company Level | |
Additional Data Analysis | |
Additional Qualitative Data | |
Additional Quantitative Data | |
Service Level Customization | Report Format Alteration |
We have various report editions of Neuropsychiatric Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Neuropsychiatric Drugs Market Analysis
Global Neuropsychiatric Drugs Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Neuropsychiatric Drugs Industry growth. Neuropsychiatric Drugs market has been segmented with the help of its Drug Type, Indication Route of Administration, and others. Neuropsychiatric Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Report scope is customizable as we have a huge database of Neuropsychiatric Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Major Drug Type Analysed |
|
Major Indication Analysed |
|
Major Route of Administration Analysed |
|
Top Manufacturers Disclosed | |
Global, Regional and Country Analysis |
|
Key Qualitative Information Covered |
|
Drug Type Segment Analysis of Neuropsychiatric Drugs Market
Based on present and future trends, the market size is estimated from 2018 to 2030. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Neuropsychiatric Drugs market.
Drug Type of Neuropsychiatric Drugs analyzed in this report are as follows:
- Typical antipsychotics
- Atypical antipsychotics
Neuropsychiatric Drugs Market Share (%) by Drug Type in 2018-2030
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Neuropsychiatric Drugs Industry. Request a Free Sample PDF!
Indication Segment Analysis of Neuropsychiatric Drugs Market
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Neuropsychiatric Drugs from 2018 to 2030. This will also help to analyze the demand for Neuropsychiatric Drugs across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.
Some of the key Indication of Neuropsychiatric Drugs are:
- Bipolar disorder
- Schizophrenia
- Psychotic depression
- Others
Neuropsychiatric Drugs Market Share (%) by Indication in 2018-2030
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Neuropsychiatric Drugs market report 2023 Edition by contacting our team.
Neuropsychiatric Drugs Route of Administration Segment Analysis
- Parenteral route
- Oral route
Neuropsychiatric Drugs Market Regional Analysis
Region and country analysis section of Neuropsychiatric Drugs Industry Analysis has been segmented into 5 major region such as North America, Europe, Asia Pacific, Middle East & Africa ,and Latin America (along with respective major contributing countries) and provides the revenue share, current trends.
The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of Neuropsychiatric Drugs market.
Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Neuropsychiatric Drugs Market Share (%) by Region (2018-2030)
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.Top Companies in Neuropsychiatric Drugs Market
Competitive Landscape includes company profiling of the key manufacturers listed below. It also provides the key developments such as new product launches, expansion, mergers & acquisitions, partnerships, agreements, joint ventures, business overview, key strategies and financial analysis associated with the key players. Strategy implemented to overcome the COVID-19 Impact will be discussed in the report scope. Key players Financials includes Revenue (USD Million), Gross Margin (%) and Market Share (%) (2018- 2022), S.W.O.T Analysis, (To read more request the sample pages Or speak to analyst/author directly).
Top Companies Market Share in Neuropsychiatric Drugs Industry: (In no particular order of Rank)
- Novartis
- Pfizer
- Otsuka
- Allergan
- Eli Lilly
- Sunovion
- Astrazeneca
- Actavis Laboratories
- Johnson & Johnson
- Bristol Myers
- Sage Therapeutics
- Blackthorn Therapeutics
- H Lundbeck A/S
- Takeda
- Cerevel Therapeutics Llc
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Neuropsychiatric Drugs Market is witnessing significant growth in the near future.
In 2022, the Typical antipsychotics segment accounted for noticeable share of global Neuropsychiatric Drugs Market and is projected to experience significant growth in the near future.
The Bipolar disorder segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Novartis, Otsuka and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Author's Detail
Surabhi Bhaiyya, LinkedIn
Senior Research Analyst at Cognitive Market Research
Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry. To get in touch and access the above report book an apointment at https://calendly.com/speak-to-analyst.
Key Questions Answered By Neuropsychiatric Drugs Market Report 2023
Why Typical antipsychotics have a significant impact on Neuropsychiatric Drugs market? |
What are the key factors affecting the Typical antipsychotics and Atypical antipsychotics of Neuropsychiatric Drugs Market? |
What is the CAGR/Growth Rate of Bipolar disorder during the forecast period? |
By type, which segment accounted for largest share of the global Neuropsychiatric Drugs Market? |
Which region is expected to dominate the global Neuropsychiatric Drugs Market within the forecast period? |
Frequently Asked Questions
- Measures to Explore Untapped Market
- Understanding Market Dynamics
- Understanding Changing Economics
- Competitors Market Share
- Global/Region/Country Level Analysis
- Identify Upcoming End Use Industries
- Global Price Trend Analysis
- Value Chain Analysis
- Customer Sentiment/Need Analysis
- Identification of Key Growth Segments
- Industry Upstream and Downstream Analysis
- Raw Material Sourcing and Cost Analysis
- Identify Key Customers Across Globe
- Concept Development and Market Testing
- Merger-Acquisition Strategy
- The research study and report are been made exclusively for an institution or person who is strategizing to build a business or strategically wants to expand certain portfolio.
- This report will help in analyzing complete market scenario across the globe who wish to expand their current business or is willing to invest in some profitable sector.
- This report will prove beneficial for person or an organization who wish to be updated regarding their business environment, consumers’ behaviour, and their requirements. The environment is constantly changing, and in such scenario, this report will help in understanding market parameters through 360-degree view.
- The report is thus ideal for KOL, CEO's, CFO's, directors, and others. It is also helpful to senior executives, business development managers, marketing managers, and consultants. Furthermore, government bodies, agencies and other kind of organizations can also leverage our report to understand market.
- Our objective for the Neuropsychiatric Drugs market is to help in making imperative business decisions, securing investments, determining new business opportunities in the market. Further, the report helps to analyze overall marketing needs of customers, and avoid business failures.
- To know the potential market size and growth rate before launching a new product line. The report in a way helps in designing R&D budget wisely by estimating maximum total profit.
- To identify the Neuropsychiatric Drugs market dynamics, industrial insights, and economic progression for critical information about the market conditions and specific business landscape.
- To assess the overall competitive landscape of a particular business sector and to provide complete analysis in regards with various external factors impacting the market growth.
- To create a strong foundation for building a strategy and foster insight into market conditions so that market players can make better business decisions. Besides, we aim to provide a complete portfolio of the major players involved the market.
- To define the scope which will further help in creating new products that will surpass the gap between current offerings and customers’ needs.
- To help in revealing significant clues concerning buying habits, regional culture, lifestyle, and population density that plays an integral role in shaping market behavior.
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market.
- Competitors Analysis: We provide data from the supplier side covering key details such as market share split among 1st tier, 2nd tier, and 3rd tier, Emerging Players, and Start-Ups. (whereas most of our competitors published data for top-tier companies)
- We provide market revenue share not only for Public listed companies but also the privately listed companies.
- Country Analysis: The Country level market split analysis is part of the report hence the data granularity is provided.
- We have been closely working with the Top 500 Fortune businesses, our clientele spanning 20+ industries. Our clientele is a mix of investors, manufacturers, end-users, distributors, etc. With our data subscription model (Athenaeum) 70% of clients have already subscribed/purchased reports for multiple years which helped us achieve unbelievable client retention statistics.
- Product + Service: In terms of the product we deliver the report access (PDF+ PPT+ EXCEL+ Cloud+ POWER BI) whereas in terms of service; we provide data support where a dedicated research analyst will be assigned and add-on benefits. (Whereas most of our competitors believe only in delivering the data/report and service and support remain questionable.)
- Credibility and Data Accuracy: We deliver accuracy close to 90-95% with the help of our in-house research team, freelancer, and industry expert network, sources present worldwide. This Data is backed up by strong What are our clients saying about our services.
Read more